Statement: Zantac (ranitidine) litigation – Joiner case

• Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
• Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer
• GSK will continue to vigorously defend itself against all other claims

GSK plc (LSE/NYSE: GSK) welcomes today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff's ability to request punitive damages.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.